Gross profit
5Y CAGR +5.8%10Y CAGR +3.7%$38.1B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
No quarters filed for this figure.
SNY
$47.47+4.72%
as of close, Nov 4, 2026
☾ AH $47.47 +4.72%
Sanofi ADSStock · Healthcare
Head-to-head:Compare with GSK or any ticker →
SNY financial statements
The full income statement, balance sheet, and cash-flow statement for Sanofi ADS (SNY), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Financial overview#
Operating income
5Y CAGR −14.9%5Y CAGR −14.9%$7.2B FY25
FY17FY18FY19FY20FY21FY22FY23FY24FY25
No quarters filed for this figure.
Net income
5Y CAGR −8.8%10Y CAGR +6.2%$8.9B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
No quarters filed for this figure.
EPS (diluted)
5Y CAGR −8.3%10Y CAGR +7.2%$3.60 FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
No quarters filed for this figure.
Operating cash flow
5Y CAGR +7.5%10Y CAGR +2.8%$12.2B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
No quarters filed for this figure.
Capital expenditure
5Y CAGR +11.0%5Y CAGR +11.0%$4B FY25
FY19FY20FY21FY22FY23FY24FY25
No quarters filed for this figure.
Free cash flow
5Y CAGR +6.1%5Y CAGR +6.1%$8.2B FY25
FY19FY20FY21FY22FY23FY24FY25
No quarters filed for this figure.
Shares (diluted)
5Y −2.7%10Y −7.2%2.5B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
No quarters filed for this figure.
Dividend per share
5Y CAGR +4.3%10Y CAGR +3.4%$2.22 FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
No quarters filed for this figure.
Shares outstanding (point-in-time)
2017-12 2.51B2018-12 2.49B2019-12 2.51B2020-12 2.50B2021-12 2.53B2022-12 2.52B2023-12 2.53B2024-12 2.53B2025-12 2.44B-2.8% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 38.1B+13.3% | 33.6B+7.2% | 31.4B+3.9% | 30.2B-5.2% | 31.8B+10.8% | ||
| Cost of revenue | 14.8B+3.4% | 14.3B+4.6% | 13.7B+9.3% | 12.5B-13.8% | 14.5B+4.6% | |
| Research & development | 8.87B+10.9% | 8.00B+13.7% | 7.04B+2.9% | 6.84B+1.6% | 6.73B+6.8% | |
| Operating income | 7.18B-8.5% | 7.84B+4.2% | 7.53B-29.6% | 10.7B+11.2% | 9.61B-40.3% | |
| Interest expense | 637M-45.1% | 1.16B-17.0% | 1.40B+209.1% | 452M+3.9% | 435M-1.6% | |
| Income tax | 1.18B-9.4% | 1.30B+18.4% | 1.10B-45.2% | 2.01B+9.0% | 1.84B-10.6% | |
| 8.88B+46.2% | 6.08B+3.4% | 5.88B-34.1% | 8.93B+20.2% | 7.43B-47.2% | ||
| Net income to common | 8.84B+47.0% | 6.01B+3.0% | 5.84B-33.7% | 8.81B+19.6% | 7.36B-47.5% | |
| $3.60+50.4% | $2.40+3.0% | $2.33-33.6% | $3.50 | — | ||
| EPS (basic) | $3.62+50.8% | $2.40+3.0% | $2.33-33.8% | $3.52 | — | |
| Weighted-avg shares (basic) | 2.44B-2.5% | 2.50B-0.0% | 2.50B-0.0% | 2.50B-0.0% | 2.50B-0.1% | |
| Weighted-avg shares (diluted) | 2.45B-2.4% | 2.51B-0.0% | 2.51B-0.0% | 2.51B-0.1% | 2.52B-0.2% | |
| Dividends per share | $2.22+9.1% | $2.03+5.6% | $1.92+9.9% | $1.75-7.4% | $1.89+5.4% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 36.4B-17.8% | 44.3B+30.7% | 33.9B-7.2% | 36.5B | — | ||
| Cash & equivalents | 9.00B+16.4% | 7.73B-19.6% | 9.62B-29.4% | 13.6B+19.2% | 11.4B-33.2% | |
| Inventory | 12.0B+22.5% | 9.80B-8.1% | 10.7B+11.3% | 9.59B-2.9% | 9.87B-3.9% | |
| 149B+8.0% | 138B-1.1% | 140B+3.0% | 136B-0.4% | 136B-3.2% | ||
| Property, plant & equipment | 11.8B+12.7% | 10.5B-6.5% | 11.2B+6.2% | 10.6B-7.0% | 11.4B-1.4% | |
| Goodwill | 48.6B+7.7% | 45.1B-17.3% | 54.5B+2.2% | 53.4B-1.9% | 54.4B-0.3% | |
| Total non-current assets | 113B+20.2% | 93.8B-11.3% | 106B+6.7% | 99.1B-2.3% | 101B+2.3% | |
| Total current liabilities | 33.3B+9.9% | 30.3B+13.4% | 26.7B+4.2% | 25.7B | — | |
| Long-term debt | 16.8B+36.7% | 12.3B-22.6% | 15.8B-0.4% | 15.9B-18.0% | 19.4B-20.2% | |
| 83.9B+4.2% | 80.6B-1.4% | 81.7B+2.2% | 80.0B+2.9% | 77.8B+0.2% | ||
| Total equity incl. non-controlling | 84.3B+4.2% | 80.9B-1.4% | 82.1B+2.1% | 80.4B+2.9% | 78.2B+0.5% | |
| Common shares issued | 2.44B | — | 2.53B+0.2% | 2.52B-0.2% | 2.53B+0.4% | |
| Shares outstanding (cover) | 2.44B-3.5% | 2.53B-0.1% | 2.53B+0.3% | 2.52B-0.2% | 2.53B+1.0% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Cash from operations | 12.2B+23.8% | 9.82B-11.5% | 11.1B+0.2% | 11.1B-11.0% | 12.4B+47.1% | |
| Capital expenditure | 4.00B+15.8% | 3.46B+10.0% | 3.14B+42.0% | 2.21B-8.4% | 2.42B+1.7% | |
| Free cash flow | 8.16B+28.2% | 6.37B-19.9% | 7.95B-10.3% | 8.86B-11.6% | 10.0B+64.9% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt issued | 6.29B | 0.00-100.0% | 51.9M-96.8% | 1.63B | 0.00-100.0% | |
| Long-term debt repaid | 2.97B+308.8% | 726M-81.8% | 3.98B+39.3% | 2.86B+7.9% | 2.65B-41.2% | |
| Common stock issued | 200M-1.0% | 202M-4.1% | 211M+6.6% | 198M-10.1% | 220M-4.9% | |
| Common stock repurchased | 5.67B+1637.1% | 327M-49.1% | 641M+22.7% | 523M+15.7% | 452M-51.8% | |
| Dividends paid | 5.40B+6.1% | 5.09B+5.6% | 4.82B+9.9% | 4.38B-7.5% | 4.74B+5.6% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 118B-3.0% | 122B-2.8% | 125B+2.5% | 122B-3.3% | 127B+4.2% | |
| P/E | 13.3×-33.6% | 20.0×+42.7% | 14.1×-14.7% | 16.5×-3.3% | 17.0×+97.2% | |
| P/B | 1.4×-6.9% | 1.5×-3.5% | 1.6×-0.4% | 1.6×-3.3% | 1.6×+4.0% | |
| P/FCF | 14.5×-24.3% | 19.1×+35.2% | 14.2×+16.0% | 12.2×-3.3% | 12.6×-36.8% | |
| Earnings yield | 7.5%+50.7% | 5.0%-29.9% | 7.1%+17.3% | 6.1%+3.4% | 5.9%-49.3% | |
| FCF yield | 6.9%+32.1% | 5.2%-26.0% | 7.1%-13.8% | 8.2%+3.4% | 7.9%+58.3% | |
| Dividend yield | 4.6%+8.5% | 4.2%+8.9% | 3.9%+7.0% | 3.6%-4.2% | 3.8%+2.2% | |
| Source filing | 20-F | 20-F | 20-F | 20-F | 20-F |
About this data
Source: SNY’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all SNY filings on SEC EDGAR → Not investment advice.
Head-to-head:Compare with GSK or any ticker →